Loading company…
San Francisco-area biotech developing engineered natural killer cell therapies for cancer treatment.
Founded in 2015 and based in California, US, Nkarta, Inc. develops advanced cell therapies, including engineered Natural Killer (NK) cells, to improve cancer treatment across diverse patient populations. In March 2024 it raised USD 240 million in PIPE funding from investors including Adage Capital Management, Boxer Capital, Commodore Capital and OrbiMed Advisors, selling 21.01 million shares of common stock and pre-funded warrants at USD 9.9 per share. The company trades on NASDAQ under the ticker NKTX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in